CD33 and neoplasm: Notably, compared to untreated AML tumor cells, those that relapsed after CAR33-T cell therapy demonstrated a downregulation of CD33 and an upregulation of CSC markers, such as SOX2 and OCT3/4 (Fig. 5f, g, m, n)82.